The combination was associated with deep and durable responses in previously untreated high-risk CLL, SLL, and del(17p) and/or TP53 mutations.
High-risk participants with heavily pre-treated relapsed or refractory follicular lymphoma benefitted in clinical remission and survival outcomes.
In a heavily pretreated population of participants with KMT2A rearranged acute leukaemia, revumenib displayed encouraging anti-tumour activity.
Sovleplenib was associated with early and durable platelet responses in participants with primary immune thrombocytopenia.
Harmful environmental influences, such as air and noise pollution or light pollution at night, can also contribute to susceptibility to disease.
Renizgamglogene autogedtemcel (reni-cel) established a swift and durable normalisation in haemoglobin and improvements in haemolysis markers.
Asciminib was superior to all other tested first-line tyrosine kinase inhibitors (TKIs) in participants with chronic myeloid leukaemia (CML).
Epcoritamab delivered encouraging efficacy data and a favourable safety profile in participants with high-risk Richter’s transformation (RT).
Mitapivat improved Hb levels and fatigue in participants with non-transfusion-dependent alpha or beta thalassaemia (NTDT) in a phase 3 study.
Treatment with pelabresib plus ruxolitinib was associated with improvements in all 4 hallmarks of myelofibrosis, the phase 3 MANIFEST-2 trial showed.
JAK inhibitor-naïve participants with myelofibrosis benefitted from a regimen of navitoclax plus ruxolitinib compared with ruxolitinib and a placebo.
The intestinal microbiome is essential in many body processes. Could prebiotic food intake benefit intestinal flora in intestinal polyps or colorectal carcinoma?
Anitocabtagene autoleucel (anito-cel) yielded excellent efficacy results in heavily pre-treated participants with relapsed or refractory multiple myeloma.
Isatuximab with bortezomib, lenalidomide + dexamethasone yielded better outcomes than VRd alone for first-line treatment of transplant-ineligible cases.
Treatment led to high measurable residual disease-negativity rates in European LeukaemiaNet subgroups for newly-diagnosed acute myeloid leukaemia.
The combination delivered a high rate of durable complete metabolic responses regardless of cell of origin in aggressive B-cell lymphoma patients.
Acalabrutinib added to bendamustine and rituximab decreased disease progression or death risks compared with BR and a placebo for mantle cell lymphoma.
An AI algorithm called "Sturgeon" can classify CNS tumours fast and accurately during surgery. This enables resection strategies adapted to tumour types.
Belantamab mafodotin plus pomalidomide and dexamethasone PVd for progression-free survival in participants with relapsed or refractory multiple myeloma.
High-risk diffuse large B-cell lymphoma patients with a complete metabolic response (CMR) after R-CHOP benefitted from atezolizumab consolidation therapy.